Not enough fluids? Drink more. Too much fluid – entirely different, far more complex problem. From the systemic swelling caused by congestive heart failure to the localized ascites caused by cancer, or NASH, Sequana Medical h...

Turning a biological process on or off is like flipping a light switch. However, these approaches often come with serious side effects that can limit therapeutic utility. For this reason, treating certain types of CNS disorde...

Harpreet co-founded Immatics in 2000 to translate pioneering scientific discoveries in immunology into highly innovative immunotherapies to impact the lives of cancer patients.

Hear how Captor Therapeutics became a Swiss/Polish public biotech company run by a Scotsman –as told by 30-year healthcare industry veteran and Captor’s CEO, Dr. Tom Shepherd. That’s one great story – another is how Captor’s ...

For the computer expert/CEO of Anima, Yochi Slonim, it’s all the same – lots of instructions and lots of code. It could be code for AI, it could be codons for the translation of proteins. With the elucidation of unique …

Your GI team can’t help you if they can’t see what’s wrong. An endoscope might encounter clotted blood in the esophagus from chronic bleeds, or remaining stool in the colon after an insufficient prep. Either way, it would be ...

Three facts: 1) World Diabetes Day is November 14th, which marks the 100th anniversary of the discovery and isolation of insulin. 2) There are an estimated 463 million diabetes patients worldwide – and that number is rapidly ...

He’s got patents, patience, and a plan – and a five-year runway to execute. Listen in as Dr. Amit Kumar, CEO of Anixa Biosciences, tells a tale of novel vaccines for breast, and ovarian cancer, and a new kind of …

From a doctorate at the SALK Institute overlooking La Jolla Cove, to an MBA from INSEAD, the world-leading business school located near Paris, NOXXON CEO Aram Mangasarian knows his way around different environments. Now he’s ...

After spending the first half of her career developing medical devices for others, Kathy Lee-Sepsick, founder, and CEO of Femasys sets out to address the often-overlooked needs of a woman’s reproductive health – and she can’t...

From a famous pub in Oxford to a lab on California’s coast, Gritstone founder, and CEO Dr. Andrew Allen tells the story of how his dream, inspired by a legend in cancer immunotherapy, became the reality that is Gritstone bio,...

Listen in while Vincerx CEO, Dr. Ahmed Hamdy shares his experience with life-changing events, a date with the cancer target CDK9, and the utterance of every investor’s favorite magic word: “Platform.”

Angion Biomedica Corp. Podcast Episode

Dr. Marshall Fordyce, CEO of Vera Therapeutics still treats patients – it is a calling he will always hear. It took him to the bedside at HIV clinics in the East to leadership roles in developing life-saving drugs at Gilead …

Christopher Giordano, MS, explains how an American English major studying at Oxford University lucked into marrying a Welsh girl he convinced to move to North Carolina’s Research Triangle – a hotbed of literary studies. From ...

You can fight fire with fire – it’s a thing. The problem is having anything left to salvage after the fire is out, and thus the conundrum of IL-2: the cytokine’s ability to supercharge T cells against cancer has been …

The field of cancer immunotherapy exploded in 2011 with the FDA approval of an utterly novel, so-called “checkpoint” drug, the anti-CTLA-4 agent, Yervoy. The fires of that first-in-class success ignited a drug development roc...

The field of cancer immunotherapy exploded in 2011 with the FDA approval of an utterly novel, so-called "checkpoint" drug, the anti-CTLA-4 agent, Yervoy. The fires of that first-in-class success ignited a drug development roc...

To the oncologist, human physiology is a riot of redundancies, and treating cancer is a game of whack-a-mole – target one mechanism, another pops up. Anat Cohen-Dayag, scientist and CEO of Compugen has known this for years. H...

GeNeuro's CEO, Jesus Martin-Garcia, a consummate technology entrepreneur, tells his business journey from the birth of telecoms, to the advent of online grocery shopping, to his support and exploration of the final frontier i...

Can T cells be leveraged as a cancer therapeutic? Check. How about natural killer (NK) cells? Check. Now meet invariant natural killer (iNKT) cells – a potentially game-changing tool to reprogram the innate and adaptive immun...

There are no approved treatments to treat dry macular degeneration – a disease of the eye that can lead to eventual blindness. The standard of care for these patients consists of functional/behavioral training to acclimate th...

From a training at the bedside to a benchtop at the NIH, to the realities of life on the Dark Side, Arcellex CMO, Dr. Chris Heery speaks of his passion of all things immunologic, and in particular, the Arcellx platform …

Dr. Jennifer Bath, an expert in antibody discovery, as well as translational work in infectious disease, explains why leaving a tenured professorship was a price worth paying to become the CEO of ImmunoPrecise Antibodies (IPA...